SCHEMBL7576345

SCHEMBL7576345

COC(=O)c1ccc(C(=O)O)cc1-c1ccccc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.45
SLC6A3 Q01959 5/20 0.44
SLC6A4 P31645 3/20 0.44
SLC6A2 P23975 1/20 0.44
NR1H4 Q96RI1 1/20 0.44
PTPRC P08575 2/20 0.44
TSHR P16473 1/20 0.43
LTB4R Q15722 1/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
GLA P06280 2/20 0.43
GAA P10253 2/20 0.43
HPGD P15428 2/20 0.43
ATM Q13315 2/20 0.43
MAPT P10636 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PLA2G7 Q13093 2/20 0.43
MCL1 Q07820 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7570354 0.91 KDM4E (0.53) SLC6A3SLC6A4SLC6A2TSHRKDM4E
SCHEMBL6573989 0.88 SLC6A3 (0.48) TTRSLC6A3SLC6A4SLC6A2PTPRC
SCHEMBL629880 0.86 MYC (0.54) TTRNR1H4PTPRCTSHRKDM4E
SCHEMBL27532181 0.85 TSHR (0.51) TTRSLC6A3SLC6A4SLC6A2PTPRC
SCHEMBL6985711 0.84 SLC6A3 (0.49) TTRSLC6A3SLC6A4SLC6A2PTPRC
SCHEMBL2267132 0.82 SLC6A3 (0.51) SLC6A3SLC6A4SLC6A2TSHRKDM4E
SCHEMBL22256464 0.82 MAPT (0.47) SLC6A3SLC6A4SLC6A2TSHRALDH1A1
Bicarbonate SCHEMBL27492792 0.81 SLC6A3 (0.54) SLC6A3SLC6A4SLC6A2TSHRKDM4E
SCHEMBL9549 0.81 SLC6A3 (0.57) SLC6A3SLC6A4SLC6A2PTPRCTSHR
SCHEMBL1018113 0.81 KDM4E (0.53) TSHRKDM4EALDH1A1GLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0986384-B1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 2012-02-22 EP disclosed
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 US disclosed
US-6248919-B1 E.G., (2S)-2-(((5-((BUTYL(2-CYCLOHEXYLETHYL)AMINO)METHYL) -2'-METHYL(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-4-(METHYLSULFAN YL)BUTANOIC ACID, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR PRODRUG THEREOF. ABBOTT LABORATORIES 2001-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 TTR 651/4885SLC6A3 3408/4885SLC6A4 2771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.